Interaction of Candida albicans with human gut epithelium in the presence of Live Biotherapeutic Products (LBPs)
Bronwyn Smit A D , Anna Kuballa B , Samantha Coulson C and Mohammad Katouli AA School of Science, Technology and Education, University of the Sunshine Coast, Maroochydore DC, Qld 4556, Australia
B School of Health and Behavioural Sciences, University of the Sunshine Coast, Maroochydore DC, Qld 4556, Australia
C Servatus Biopharmaceuticals, Coolum Beach, Qld 4573, Australia
D Email: bronwyn.smit@research.usc.edu.au
Microbiology Australia 42(3) 120-124 https://doi.org/10.1071/MA21035
Submitted: 21 July 2021 Accepted: 30 August 2021 Published: 13 September 2021
Journal Compilation © The Authors 2021 Open Access CC BY-NC-ND, published (by CSIRO Publishing) on behalf of the ASM
Abstract
Candida albicans is a semi-ubiquitous pathobiont that is known to significantly impact human health and wellbeing, causing a significant financial strain on the medical system. Due to increasing antifungal resistance, there is a growing need for novel fungal therapeutics to treat diseases caused by this fungus. The development and use of Live Biotherapeutic Products (LBPs) is an innovative and novel approach to potentially treating Candidiasis and other comorbidities associated with C. albicans infection. To evaluate their anti-pathogenic efficacy, it is necessary to understand the underlying mechanisms involved, via the use of biomimetic cell models. In this study, six LBPs were chosen to investigate their competitive inhibitory effect against C. albicans using a co-culture of Caco-2 cells and mucous-secreting HT29-MTX cells to mimic human gut epithelium. The LBP strains were supplied by Servatus Biopharmaceuticals and identified as SVT 01D1, SVT 04P1, SVT 05P2, SVT 06B1, SVT 07R1 and SVT 08Z1. Five out of the six LBPs showed a significant reduction in the adhesion of C. albicans and all six LBPs reduced C. albicans invasion in the co-culture cells to varying degrees. There was no significant difference between co-inoculation of C. albicans with the LBPs or pre-inoculation of LBPs before the addition of C. albicans. The potential of these LBPs as novel anti-fungal therapeutics for the treatment of C. albicans diseases can be further documented in clinical trials.
References
[1] Schulze, J. and Sonnenborn, U. (2009) Yeasts in the gut: from commensals to infectious agents. Dtsch. Arztebl. Int. 106, 837–842.| 20062581PubMed |
[2] Myerowitz, R.L. et al. (1977) Disseminated candidiasis. Changes in incidence, underlying diseases, and pathology. Am. J. Clin. Pathol. 68, 29.
| Disseminated candidiasis. Changes in incidence, underlying diseases, and pathology.Crossref | GoogleScholarGoogle Scholar | 868803PubMed |
[3] Verghese, A. et al. (1988) Synchronous bacterial and fungal septicemia. A marker for the critically ill surgical patient. Am. Surg. 54, 276–283.
| 3364864PubMed |
[4] Kumamoto, C.A. (2011) Inflammation and gastrointestinal Candida colonization. Curr. Opin. Microbiol. 14, 386–391.
| Inflammation and gastrointestinal Candida colonization.Crossref | GoogleScholarGoogle Scholar | 21802979PubMed |
[5] Gudlaugsson, O. et al. (2003) Attributable mortality of nosocomial candidemia, revisited. Clin. Infect. Dis. 37, 1172–1177.
| Attributable mortality of nosocomial candidemia, revisited.Crossref | GoogleScholarGoogle Scholar | 14557960PubMed |
[6] Bassetti, M. et al. (2011) Epidemiology, species distribution, antifungal susceptibility and outcome of nosocomial candidemia in a tertiary care hospital in Italy. PLoS One 6, e24198.
| Epidemiology, species distribution, antifungal susceptibility and outcome of nosocomial candidemia in a tertiary care hospital in Italy.Crossref | GoogleScholarGoogle Scholar | 21935385PubMed |
[7] Jawhara, S. et al. (2008) Colonization of mice by Candida albicans is promoted by chemically induced colitis and augments inflammatory responses through galectin-3. J. Infect. Dis. 197, 972–980.
| Colonization of mice by Candida albicans is promoted by chemically induced colitis and augments inflammatory responses through galectin-3.Crossref | GoogleScholarGoogle Scholar | 18419533PubMed |
[8] Sonoyama, K. et al. (2011) Gut colonization by Candida albicans aggravates inflammation in the gut and extra-gut tissues in mice. Med. Mycol. 49, 237–247.
| Gut colonization by Candida albicans aggravates inflammation in the gut and extra-gut tissues in mice.Crossref | GoogleScholarGoogle Scholar | 20807027PubMed |
[9] Yan, L. et al. (2016) Effect of Candida albicans on intestinal ischemia-reperfusion injury in rats. Chin. Med. J. (Engl.) 129, 1711.
| Effect of Candida albicans on intestinal ischemia-reperfusion injury in rats.Crossref | GoogleScholarGoogle Scholar | 27411459PubMed |
[10] Sokol, H. et al. (2017) Fungal microbiota dysbiosis in IBD. Gut 66, 1039–1048.
| Fungal microbiota dysbiosis in IBD.Crossref | GoogleScholarGoogle Scholar | 26843508PubMed |
[11] Standaert-Vitse, A. et al. (2009) Candida albicans colonization and ASCA in familial Crohn’s disease. Am. J. Gastroenterol. 104, 1745–1753.
| Candida albicans colonization and ASCA in familial Crohn’s disease.Crossref | GoogleScholarGoogle Scholar | 19471251PubMed |
[12] Erdogan, A. and Rao, S.S. (2015) Small intestinal fungal overgrowth. Curr. Gastroenterol. Rep. 17, 16.
| Small intestinal fungal overgrowth.Crossref | GoogleScholarGoogle Scholar | 25786900PubMed |
[13] U.S. Department of Health and Human Services (2016) Early clinical trials with live biotherapeutic products: chemistry, manufacturing, and control information; guidance for industry. https://www.fda.gov/media/82945/download
[14] Rouanet, A. et al. (2020) Live biotherapeutic products, a road map for safety assessment. Front. Med. 7, 237.
| Live biotherapeutic products, a road map for safety assessment.Crossref | GoogleScholarGoogle Scholar |
[15] Charbonneau, M.R. et al. (2020) Developing a new class of engineered live bacterial therapeutics to treat human diseases. Nat. Commun. 11, 1738.
| Developing a new class of engineered live bacterial therapeutics to treat human diseases.Crossref | GoogleScholarGoogle Scholar | 32269218PubMed |
[16] Chen, X.M. et al. (2010) Defining conditions for the co-culture of Caco-2 and HT29-MTX cells using Taguchi design. J. Pharmacol. Toxicol. Methods 61, 334–342.
| Defining conditions for the co-culture of Caco-2 and HT29-MTX cells using Taguchi design.Crossref | GoogleScholarGoogle Scholar | 20159047PubMed |
[17] Béduneau, A. et al. (2014) A tunable Caco-2/HT29-MTX co-culture model mimicking variable permeabilities of the human intestine obtained by an original seeding procedure. Eur. J. Pharm. Biopharm. 87, 290–298.
| A tunable Caco-2/HT29-MTX co-culture model mimicking variable permeabilities of the human intestine obtained by an original seeding procedure.Crossref | GoogleScholarGoogle Scholar | 24704198PubMed |
[18] Hilgendorf, C. et al. (2000) Caco-2 versus Caco-2/HT29-MTX co-cultured cell lines: permeabilities via diffusion, inside- and outside-directed carrier-mediated transport. J. Pharm. Sci. 89, 63–75.
| Caco-2 versus Caco-2/HT29-MTX co-cultured cell lines: permeabilities via diffusion, inside- and outside-directed carrier-mediated transport.Crossref | GoogleScholarGoogle Scholar | 10664539PubMed |
[19] Lesuffleur, T. et al. (1990) Growth adaptation to methotrexate of HT-29 human colon carcinoma cells is associated with their ability to differentiate into columnar absorptive and mucus-secreting cells. Cancer Res. 50, 6334.
| 2205381PubMed |
[20] Poupet, C. et al. (2019) Curative treatment of candidiasis by the live biotherapeutic microorganism Lactobacillus rhamnosus Lcr35® in the invertebrate model Caenorhabditis elegans: first mechanistic insights. Microorganisms 8, 34.
| Curative treatment of candidiasis by the live biotherapeutic microorganism Lactobacillus rhamnosus Lcr35® in the invertebrate model Caenorhabditis elegans: first mechanistic insights.Crossref | GoogleScholarGoogle Scholar |
[21] Weis, A.M. and Round, J.L. (2021) Microbiota-antibody interactions that regulate gut homeostasis. Cell Host Microbe 29, 334–346.
| Microbiota-antibody interactions that regulate gut homeostasis.Crossref | GoogleScholarGoogle Scholar | 33705705PubMed |
